+关注
Finn
暂无个人介绍
IP属地:广东
16
关注
0
粉丝
0
主题
0
勋章
主贴
热门
Finn
2021-01-20
说说你对这篇新闻的看法...
抱歉,原内容已删除
Finn
2020-07-09
说说你对这篇新闻的看法...
抱歉,原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3453604361684920","uuid":"3453604361684920","gmtCreate":1490510341221,"gmtModify":1733751278425,"name":"Finn","pinyin":"finn","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/54d45f8d01cc6187332b979d2814981b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":16,"tweetSize":2,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.10","exceedPercentage":"93.86%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":337189123,"gmtCreate":1611081744562,"gmtModify":1703747940345,"author":{"id":"3453604361684920","authorId":"3453604361684920","name":"Finn","avatar":"https://static.tigerbbs.com/54d45f8d01cc6187332b979d2814981b","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3453604361684920","authorIdStr":"3453604361684920"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/337189123","repostId":"2104149292","repostType":2,"isVote":1,"tweetType":1,"viewCount":1380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":949585933,"gmtCreate":1594272856022,"gmtModify":1704204854976,"author":{"id":"3453604361684920","authorId":"3453604361684920","name":"Finn","avatar":"https://static.tigerbbs.com/54d45f8d01cc6187332b979d2814981b","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3453604361684920","authorIdStr":"3453604361684920"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/949585933","repostId":"2050140260","repostType":2,"isVote":1,"tweetType":1,"viewCount":2269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":337189123,"gmtCreate":1611081744562,"gmtModify":1703747940345,"author":{"id":"3453604361684920","authorId":"3453604361684920","name":"Finn","avatar":"https://static.tigerbbs.com/54d45f8d01cc6187332b979d2814981b","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3453604361684920","authorIdStr":"3453604361684920"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/337189123","repostId":"2104149292","repostType":2,"isVote":1,"tweetType":1,"viewCount":1380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":949585933,"gmtCreate":1594272856022,"gmtModify":1704204854976,"author":{"id":"3453604361684920","authorId":"3453604361684920","name":"Finn","avatar":"https://static.tigerbbs.com/54d45f8d01cc6187332b979d2814981b","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3453604361684920","authorIdStr":"3453604361684920"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/949585933","repostId":"2050140260","repostType":2,"repost":{"id":"2050140260","kind":"news","pubTimestamp":1594218300,"share":"https://www.laohu8.com/m/news/2050140260?lang=&edition=full","pubTime":"2020-07-08 22:25","market":"us","language":"zh","title":"上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2050140260","media":"澎湃新闻","summary":"原标题:上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发新冠肺炎疫情暴发以来,在没有特效治疗药物的情况下,预防性质的新冠疫苗一直备受关注,新冠疫苗的每一步进展都牵动着人们的心。据科技部、国家卫","content":"<div>\n<p>原标题:上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发新冠肺炎疫情暴发以来,在没有特效治疗药物的情况下,预防性质的新冠疫苗一直备受关注,新冠疫苗的每一步进展都牵动着人们的心。据科技部、国家卫健委6月19日的通报,中国科研攻关团队按照灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗(mRNA和DNA疫苗都属于核酸疫苗范畴)等5条技术路线,共布局了12项疫苗...</p>\n\n<a href=\"http://cj.sina.cn/article/normal_detail?url=https://tech.sina.com.cn/roll/2020-07-08/doc-iircuyvk2763723.shtml\">Web Link</a>\n\n</div>\n","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-07-08 22:25 北京时间 <a href=http://cj.sina.cn/article/normal_detail?url=https://tech.sina.com.cn/roll/2020-07-08/doc-iircuyvk2763723.shtml><strong>澎湃新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>原标题:上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发新冠肺炎疫情暴发以来,在没有特效治疗药物的情况下,预防性质的新冠疫苗一直备受关注,新冠疫苗的每一步进展都牵动着人们的心。据科技部、国家卫健委6月19日的通报,中国科研攻关团队按照灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗(mRNA和DNA疫苗都属于核酸疫苗范畴)等5条技术路线,共布局了12项疫苗...</p>\n\n<a href=\"http://cj.sina.cn/article/normal_detail?url=https://tech.sina.com.cn/roll/2020-07-08/doc-iircuyvk2763723.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","relate_stocks":{"06185":"康希诺生物","SVA":"科兴生物"},"source_url":"http://cj.sina.cn/article/normal_detail?url=https://tech.sina.com.cn/roll/2020-07-08/doc-iircuyvk2763723.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2050140260","content_text":"原标题:上半年至少6个国产新冠疫苗进入临床试验,还有更多正在研发新冠肺炎疫情暴发以来,在没有特效治疗药物的情况下,预防性质的新冠疫苗一直备受关注,新冠疫苗的每一步进展都牵动着人们的心。据科技部、国家卫健委6月19日的通报,中国科研攻关团队按照灭活疫苗、基因工程重组亚单位疫苗、腺病毒载体疫苗、减毒流感病毒载体疫苗和核酸疫苗(mRNA和DNA疫苗都属于核酸疫苗范畴)等5条技术路线,共布局了12项疫苗研发任务。澎湃新闻记者根据公开报道梳理发现,国内目前至少有6个国产新冠疫苗进入临床试验阶段,其中康希诺生物与军事科学院军事医学研究院生物工程研究所陈薇院士团队联合开发的Ad5-nCoV疫苗走在前列。根据公开报道梳理的国内进入临床试验阶段的新冠疫苗康希诺生物:获得军队特需药品批件6月25日,康希诺生物(06185.HK)公布,获得中央军委后勤保障部卫生局颁发的军队特需药品批件,有效期一年。康希诺生物的Ad5-nCoV疫苗是与军事科学院军事医学研究院生物工程研究所陈薇院士团队联合开发,I期及II期临床试验阶段就备受关注。6月11日,Ad5-nCoV疫苗完成II期临床试验揭盲,总体试验结果表明,Ad5-nCoV具有预防由SARS-CoV-2引起的疾病的潜力。根据《中国人民解放军实施<中华人民共和国药品管理法>办法》规定, Ad5-nCoV现阶段仅限于军队内部使用,未经军委后勤保障部批准,不得扩大接种范围。康希诺生物也提醒,“我们无法保证我们将能最终成功商业化Ad5-nCoV。”值得一提的是,6月初,曾有消息称,陈薇院士团队新冠疫苗将在贵州投产,康熙诺生物对此特别发表声明,强调公司拥有Ad5-nCoV的生产和商业化的全部权利。中国生物“双响炮”:建成新冠疫苗生产车间6月28日,国药集团中国生物北京生物制品研究所与中国疾病预防控制中心病毒病预防控制所共同研制的新冠病毒灭活疫苗Ⅰ/Ⅱ期临床试验揭盲,结果显示,疫苗接种后安全性好,不同程序、不同剂量接种后,疫苗组接种者均产生高滴度抗体,0,21天程序接种两剂后中和抗体阳转率达100%,0,28天程序接种两剂后中和抗体阳转率达100%。而此前的6月16日,国药集团中国生物武汉生物制品研究所研制的新冠病毒灭活疫苗Ⅰ/Ⅱ期临床试验揭盲,结果显示,疫苗组接种者均产生高滴度抗体,0,28天程序接种两剂后,中和抗体阳转率达100%。除了疫苗研发,国药系在疫苗生产方面也跨出了一大步,北京生物制品研究所已经建成了全国首个、唯一的高等级生物安全生产设施,投入使用后新冠疫苗产能将达到年产1.2亿剂,这也是目前全球最大的新冠灭活疫苗生产车间。此前也有消息,国药集团中国生物武汉生物制品研究所新冠灭活疫苗车间建设预计将于6月底或7月初完成。值得一提的是,中国生物并非一家上市公司,旗下拥有上市公司天坛生物(600161.SH),天坛生物的主营业务是血液制品的研发、制造、销售及咨询服务,也没有直接参与新冠疫苗。中国生物的两款生物疫苗倒是让“沾亲带故”的国药股份、国药一致等上市公司股价上涨,甚至涨停。不过,6月24日国药股份发布公告,称“不涉及疫苗研发生产,与中国生物无股权关系,中国生物与国药股份为同一实际控制人”,端午假期后开盘首日的6月29日,国药股份即遭遇跌停。科兴生物:Ⅰ/Ⅱ期临床研究揭盲6月14日,美股上市公司科兴生物(SVA.US)发布消息,称旗下北京科兴中维生物技术有限公司(简称“科兴中维”) 研制新冠疫苗Ⅰ/Ⅱ期临床研究(0,14程序)揭盲,初步结果显示该疫苗具有良好的安全性和免疫原性。 这项随机、双盲、安慰剂对照的Ⅰ/Ⅱ期临床研究负责机构为江苏省疾病预防控制中心(江苏省公共卫生研究院),研究的目的是评价不同剂量的新型冠状病毒灭活疫苗按照0,14程序或0,28程序接种健康受试者的安全性、耐受性和免疫原性,确定疫苗的免疫程序和免疫剂量。科兴生物称,I/Ⅱ期临床研究受试者共743人已全部完成接种。智飞生物、沃森生物:拿到临床试验批件相比较已揭盲的新冠疫苗,智飞生物和沃森生物在新冠疫苗的进度刚刚开始。智飞生物(300122,SZ)6月23日发布公告称,全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)与中国科学院微生物研究所合作研发的重组新型冠状病毒疫苗(CHO 细胞)获得国家药品监督管理局临床试验申请受理通知书及临床试验批件。据悉,这是中国首个重组亚单位新冠疫苗,也是全球第二个进入临床试验的重组亚单位新冠疫苗。6月28日,沃森生物(300142,SZ)发布公告称,近日收到国家药品监督管理局批准的新型冠状病毒mRNA疫苗《药物临床试验批件》,该疫苗是沃森生物与中国人民解放军军事科学院军事医学研究院、苏州艾博生物科技有限公司共同研发。沃森生物称,此次获批的新冠疫苗是中国首个获批进入临床试验阶段的mRNA新型冠状病毒疫苗,目前仅有美国、德国等少数几个国家的新型冠状病毒mRNA疫苗进入临床试验阶段,此前中国尚未批准过mRNA疫苗进入临床试验。上海的新冠人源细胞疫苗:商业化情况未知2月26日,上海公共卫生临床中心的徐建青研究员给自己注射了一针新冠核酸(DNA)疫苗。这种新冠疫苗是人源细胞载体疫苗,优点是只需要做细胞扩增,省去了病毒接种、扩增和纯化的步骤,因此生产会速度会更快。据第一财经3月8日报道称,徐建青团队已经在与下游的厂商对接。不过,目前该疫苗的商业化将与哪家企业合作,还没有准确消息。更多国产新冠疫苗在研发6月15日,西藏药业(600211.SH)宣布与斯微(上海)生物科技有限公司(简称“斯微生物”)合作研发,并获得相关疫苗的全球独家开发、注册、生产、使用及商业化权利,相关疫苗包括新冠疫苗。受该利好消息,西藏药业6月16日、6月17日连续涨停。6月17日,西藏药业公告称,仅获得相关疫苗的全球独家开发、生产、使用及商业化权利,公司不成为相关疫苗的权益所有人,且相关疫苗处于临床前研究阶段。同样位于临床前研究阶段的还有华兰生物(002007.SZ)。6月18日,华兰生物在互动平台称,正积极开展新冠疫苗的研发,同时新建了P3生产车间和实验室。其6月24日又称,新冠疫苗“目前还在临床前研究阶段”。此外,欧林生物、冠昊生物、康泰生物、成大生物等上半年也曾曝出新冠疫苗相关消息,但并没有披露进一步的消息。2020年下半年,新冠疫苗研发仍然值得期待。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}